Phase I Study of Lonafarnib (SCH66336) and Gleevec (Imatinib Mesylate) in Chronic Myelogenous Leukemia (CML).
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Imatinib (Primary) ; Lonafarnib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 20 Feb 2012 Additional lead trial investigator (Cortes JE) and actual patient no (23) identified as reported by ClinicalTrials.gov.
- 31 Oct 2006 Status change
- 06 Oct 2005 New trial record.